ABSTRACT
Although the range of immune responses to COVID-19 infection is variable, cytokine storm is observed in many affected individuals. To further understand the disease pathogenesis and, consequently, to develop an additional tool for clinicians to evaluate patients for presumptive intervention we sought to compare plasma cytokine levels between a range of donor and patient samples grouped by a COVID-19 Severity Score (CSS) based on need for hospitalization and oxygen requirement. Here we utilize a mutual information algorithm that classifies the information gain for CSS prediction provided by cytokine expression levels and clinical variables. Using this methodology, we found that a small number of clinical and cytokine expression variables are predictive of presenting COVID-19 disease severity, raising questions about the mechanism by which COVID-19 creates severe illness. The variables that were the most predictive of CSS included clinical variables such as age and abnormal chest x-ray as well as cytokines such as macrophage colony-stimulating factor (M-CSF), interferon-inducible protein 10 (IP-10) and Interleukin-1 Receptor Antagonist (IL-1RA). Our results suggest that SARS-CoV-2 infection causes a plethora of changes in cytokine profiles and that particularly in severely ill patients, these changes are consistent with the presence of Macrophage Activation Syndrome and could furthermore be used as a biomarker to predict disease severity.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Brown University
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
COVID-19 (°) and (−) human plasma samples were received from the Lifespan Brown COVID-19 Biobank from Brown University at Rhode Island Hospital (Providence, Rhode Island). All patient samples were deidentified but included the available clinical information as described in the manuscript. The IRB study protocol Pilot Study Evaluating Cytokine Profiles in COVID-19 Patient Samples did not meet the definition of human subjects research by either the Brown University or the Rhode Island Hospital IRBs. This is based on the fact that the project used deidentified specimens from a biobank with a determination that this project did not meet the definition of human subjects research based on specific criteria as described below. The original samples were collected at Rhode Island hospital by the Lifespan Brown COVID-19 Biobank through an IRB-approved protocol that involved informed consent that was used by the biobank. For the present study, we completed a human subjects determination form for the Human Subjects Protection Program at Brown University. We explained the purpose of our research and that we would be receiving deidentified samples from the COVID-19 biobank. We further answered questions about our study that led to the determination that our study constitutes research because we answered "yes" to the following two questions: 1- Does your proposed project involve a systematic investigation: that is a prospective plan that incorporates qualitative or quantitative data collection, and data analysis to answer a question?, and 2- Is the intent of your proposed project to develop or contribute to generalizable knowledge; that is to create knowledge from which conclusions will be drawn that can be applied to populations beyond the specific population from which it was collected. In addition, we answered "no" to four questions regarding whether the project involves human subjects. The questions were 1- Does your proposed project involve an intervention: that is a physical procedure or manipulation or a living individual (or their environment) to obtain information about them? 2- Does your proposed project involve an interaction; that is communication or contact with a living individual (in person, online, or by phone) to obtain information about them? 3-Does your proposed project involve identifiable private information or identifiable biospecimen; that is receipt or collection of private information or biospecimen about a living individual to obtain information about them? and 4- Does your proposed project involve coded information/ biospecimens; that is where a link exists that could allow information about a living individual to be reidentified AND you are able to access the link? Since we answered "no" to all these questions, our proposed project did NOT involve "Human Subjects.” Based on the information included in the Human Subjects Determination Form, The Human Research Protection Program at Brown University agreed with the investigator's self-determination that the project does not meet the definition of human subjects research. This determination was made by the Human Research Protection Program at Brown University on June 17, 2020.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is contained within the manuscript or supplementary files
